Browse Studies — Arctuva

Phase 1

A Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX319 in Subjects With Primary or Secondary Progressive Multiple Sclerosis

The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary prog…

Primary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis (SPMS)Multiple Sclerosis+2 more

Estimated

~$10 – $8,750

Tr1X, Inc.NCT07477639

Phase 3

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients With Secondary Progressive Multiple Sclerosis

The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

Secondary Progressive Multiple Sclerosis (SPMS)

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07225504

Phase 2

A Double Blind, Randomized, Placebo Controlled Phase 2b Study to Evaluate the Safety and Clinical Efficacy of Treatment With the Autologous Cell Therapy Product, NG01, in Patients With Secondary Progressive Multiple Sclerosis

The goal of this clinical trial is to assess the safety and efficacy of repeated intrathecal (IT) injection of NG01, autologous bone marrow derived human strom…

Secondary Progressive Multiple Sclerosis (SPMS)

Estimated

~$10 – $8,750

NeuroGenesis Ltd.NCT06961383